The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis
Open accessPublished version of a preprint
Abstract
This large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor Necrosis Factor (TNF) blocking agent is associated with lower risk for Alzheimer's disease (AD) in patients with rheumatoid arthritis (RA), psoriasis, and other inflammatory diseases which are mediated in part by TNF and for which a TNF blocker is an approved treatment. The analysis compared the diagnosis of AD as an outcome measure in patients receiving at least one prescription for a TNF blocking agent (etanercept, adalimumab, and infliximab) or for methotrexate. Adjusted odds ratios (AORs) were estimated using the Cochran-Mantel-Haenszel (CMH) method and presented with 95% confidence intervals (CIs) and p-values. RA was associated with a higher risk for AD (Adjusted Odds Ratio (AOR) = 2.06, 95% Confidence Interval: (2.02-2.10), P-value <0.0001) as did psoriasis (AOR = 1.37 (1.31-1.42), P <0.0001), ankylosing spondylitis (AOR = 1.57 (1.39-1.77), P <0.0001), inflammatory bowel disease (AOR = 2.46 (2.33-2.59), P < 0.0001), ulcerative colitis (AOR = 1.82 (1.74-1.91), P <0.0001), and Crohn's disease (AOR = 2.33 (2.22-2.43), P <0.0001). The risk for AD in patients with RA was lower among patients treated with etanercept (AOR = 0.34 (0.25-0.47), P <0.0001), adalimumab (AOR = 0.28 (0.19-0.39), P < 0.0001), or infliximab (AOR = 0.52 (0.39-0.69), P <0.0001). Methotrexate was also associated with a lower risk for AD (AOR = 0.64 (0.61-0.68), P <0.0001), while lower risk was found in patients with a prescription history for both a TNF blocker and methotrexate. Etanercept and adalimumab also were associated with lower risk for AD in patients with psoriasis: AOR = 0.47 (0.30-0.73 and 0.41 (0.20-0.76), respectively. There was no effect of gender or race, while younger patients showed greater benefit from a TNF blocker than did older patients. This study identifies a subset of patients in whom systemic inflammation contributes to risk for AD through a pathological mechanism involving TNF and who therefore may benefit from treatment with a TNF blocking agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have demonstrated that a proinflammatory state (148–150), inflammatory disease (e.g., rheumatoid arthritis) (151), and immune challenges (e.g., acute infection) (152, 153) all increase the risk for dementia over multiple decades.”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [151]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“TLR4 encodes the Toll like receptor 4, a receptor in microglia, monocytes and macrophages that triggers TNF release when activated by lipopolysaccharide, or in the case of microglia, by amyloid beta peptide [41].”
BackgroundFate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175 · cited 1×
“Microglia cells, the resident macrophages in the brain, derive embryonically from the same myeloid stem cells in bone marrow that give rise to monocytes and macrophages elsewhere in the body [4].”
Background2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Diagnosis and Management of Rheumatoid Arthritis: A Review
Aletaha, D., & Smolen, J. S. (2018) · JAMA · doi:10.1001/jama.2018.13103 · Cited by 2,313
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“Even with carefully selected patients enrolled in large, multi-center, Phase 3 clinical trials, AD is misdiagnosed based solely on clinical criteria in up to 25% of patients [35, 36].”
BackgroundMicroglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“Neuroinflammatory changes around the amyloid plaques include reactive astrocytosis and microglial cell activation [3].”
BackgroundMicroglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767 · cited 1×
“Microglia activation and gliosis formerly were considered secondary to neurodegeneration in AD, however, recent genetic studies in late-onset AD implicate microglia- and astrocyterelated pathways in disease pathogenesis.[10, 48, 49] One focus of interest is TREM2, an innate immune receptor expressed on microglia and m…”
Result
Cited by
Wang, Q. Q., Kaelber, D. C., Xu, R., & Volkow, N. D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00880-7 · Cited by 634
Self-citationWang, Q., Xu, R., & Volkow, N. D. (2021) · World Psychiatry · doi:10.1002/wps.20806 · Cited by 617
Self-citationNeuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics
Thakur, S., Dhapola, R., Sarma, P., Medhi, B., & Reddy, D. H. (2023) · Inflammation · doi:10.1007/s10753-022-01721-1 · Cited by 557
Wang, Q., Berger, N. A., & Xu, R. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6178 · Cited by 390
Self-citationKoźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103483 · Cited by 326
Metadata
- Authors
- Zhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E.
- Affiliations
- Case Western Reserve University (US)
- MetroHealth (US)
- Tetra Therapeutics (United States) (US)
- Corresponding author
- Xu, Rong
- Gurney, Mark E.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-03-23
- Volume
- 15
- Issue
- 3
- Pages
- e0229819
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7089534
- OpenAlex
- W3012855465
- Cited by
- 157
- References
- 66
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 23 · 2023: 27 · 2022: 38 · 2021: 21 · 2020: 13
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (DP2HD084068)
- National Institute on Aging (R01 AG057557, R01 AG061388, R56 AG062272)
- American Cancer Society (RSG-16-049-01 - MPC)
- National Institute of Mental Health (MH091791, MH107077)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, TNF-alpha inhibitors, rheumatoid arthritis, psoriasis, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, etanercept, adalimumab, infliximab, methotrexate, anti-TNF therapy, neurodegeneration risk, electronic health records, pharmacoepidemiology
- MeSH terms
- Etanercept, Adalimumab, Infliximab, Tumor Necrosis Factor Inhibitors, Adolescent, Adult, Aged, Alzheimer Disease, Arthritis, Rheumatoid, Colitis, Ulcerative, Female, Humans, Male, Methotrexate, Middle Aged, Retrospective Studies, Risk, Arthritis, Psoriatic, Case-Control Studies, Antirheumatic Agents, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. https://app.cochat.ai/papers/10.1371/journal.pone.0229819
- The paper
- Zhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E. (2020). Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. PLOS ONE. https://doi.org/10.1371/journal.pone.0229819
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.